P2.09-33 A Phase II Trial of Anlotinib Plus Osimertinib in Advanced NSCLC with EGFR T790M Mutation After Failure of Prior EGFR TKIs

While osimertinib was initially highly effective for patients with epidermal growth factor receptor (EGFR) T790M resistance mutation, eventually develop acquired resistance. Considering the angiogenic pathway was involved in EGFR-tyrosine kinase inhibitor (TKI) resistance, we accessed the efficacy and safety of osimertinib combined with anlotinib in advanced non-small cell lung cancer (NSCLC) with confirmed EGFR T790M mutation after failure of prior EGFR TKIs.